Selank Peptide Shows Promise Against Genetic and Stress-Induced Depression in Animal Models

Depression is a complex and debilitating mental health condition affecting millions worldwide, often characterized by persistent sadness, loss of interest, and impaired daily functioning. Current antidepressant treatments, while effective for many, can have significant side effects and may not work for all individuals, especially those with treatment-resistant forms or specific genetic predispositions. This study addresses the critical need for novel therapeutic agents by investigating the anxiolytic (anxiety-reducing) and antidepressant potential of Selank, a synthetic peptide, across diverse animal models of depression.

Selank consistently demonstrated significant antidepressant and anxiolytic effects across all tested models. In Wistar rats, acute Selank administration led to a 35% reduction in immobility time during the forced swim test compared to controls (p<0.01), indicating potent antidepressant activity. BALB/c mice treated with 0.5 mg/kg Selank showed a 28% decrease in despair-like behavior in the tail suspension test. Chronic treatment with Selank at 1.0 mg/kg daily for 14 days in WAG/Rij rats was particularly effective. The most significant finding was in WAG/Rij rats, where chronic Selank normalized several behavioral parameters, resulting in a 43% decrease in depressive-like immobility and a 2.5-fold increase in exploratory behavior compared to untreated controls (p<0.005), highlighting its efficacy against genetically-predisposed depression. Furthermore, Selank improved coping strategies in stress-provoked models, reducing anxiety-like behaviors by 20-25% without causing sedation.